Novo Nordisk stock (DK0062498333): Citi raises price target on Wegovy pill momentum

Analyst upgrades and strong oral Wegovy launch drive Novo Nordisk higher. Citi raises price target as Danish pharma giant gains traction in weight-loss market.

Novo Nordisk gained momentum on Monday as analyst firms raised price targets following the successful launch of the oral version of Wegovy, signaling renewed confidence in the Danish pharmaceutical company's growth trajectory. The stock traded at $46.02 USD on May 11, 2026 on NYSE, according to MarketBeat as of May 11, 2026.

Citi described the launch of the oral version of Wegovy as impressive, according to MarketScreener as of May 11, 2026. The Danish pharmaceutical giant rose nearly 4 percent on the Copenhagen Stock Exchange following the analyst upgrade. SB1 Markets also reiterated its buy rating and raised its price target to DKK 350 from DKK 280, according to MarketScreener as of May 11, 2026.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk A/S
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Denmark
• Core markets: Global, with significant US presence
• Key revenue drivers: GLP-1 receptor agonists (Ozempic, Wegovy), insulin products, other diabetes and obesity treatments
• Home exchange/listing venue: NYSE (ticker: NVO)
• Trading currency: USD

Novo Nordisk: core business model

Novo Nordisk is a global pharmaceutical company headquartered in Denmark with a primary focus on diabetes care, obesity treatment, and other chronic diseases. The company operates across multiple therapeutic areas but has gained particular prominence in recent years through its GLP-1 receptor agonist portfolio, which includes Ozempic for diabetes and Wegovy for weight management. The company's business model centers on developing and commercializing innovative treatments that address significant unmet medical needs in large patient populations.

The recent launch of the oral formulation of Wegovy represents a strategic expansion of the company's obesity treatment offerings. Previously available only as an injectable, the pill form addresses patient preferences and accessibility concerns, potentially broadening the addressable market. This product innovation aligns with Novo Nordisk's strategy to maintain leadership in the rapidly growing weight-loss medication category.

Main revenue and product drivers for Novo Nordisk

Novo Nordisk's revenue is primarily driven by its diabetes and obesity portfolios. Ozempic, the injectable GLP-1 agonist for type 2 diabetes, has become a blockbuster product with significant global uptake. Wegovy, the same active ingredient formulated for chronic weight management, has experienced explosive demand since its launch, reflecting the substantial market opportunity in obesity treatment. The company reported revenue of $10.85 billion for the most recent quarter, according to MarketBeat as of May 11, 2026.

The oral Wegovy launch is expected to drive incremental revenue growth by capturing patients who prefer pill-based treatments over injections. This product form factor addresses a key barrier to adoption and positions Novo Nordisk to capture a larger share of the obesity treatment market. The company's return on equity reached 63.31%, reflecting strong profitability and efficient capital deployment in this high-demand therapeutic area.

Conclusion

Novo Nordisk's stock momentum reflects growing analyst confidence in the company's ability to capitalize on the expanding obesity treatment market through product innovation and market expansion. The successful launch of oral Wegovy, combined with positive analyst commentary from major firms like Citi and SB1 Markets, underscores the market's recognition of the company's competitive positioning. For US investors, Novo Nordisk represents exposure to a global pharmaceutical leader with significant exposure to high-growth therapeutic categories, though investors should monitor competitive dynamics and regulatory developments in the GLP-1 market.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.